SG Americas Securities LLC Sells 22,974 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

SG Americas Securities LLC decreased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 3.5% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 628,510 shares of the company’s stock after selling 22,974 shares during the period. SG Americas Securities LLC’s holdings in Teva Pharmaceutical Industries were worth $11,326,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in TEVA. New Covenant Trust Company N.A. bought a new stake in Teva Pharmaceutical Industries in the first quarter worth about $28,000. EntryPoint Capital LLC bought a new stake in Teva Pharmaceutical Industries in the first quarter worth about $30,000. Beach Investment Counsel Inc. PA bought a new stake in Teva Pharmaceutical Industries in the second quarter worth about $48,000. Byrne Asset Management LLC bought a new stake in Teva Pharmaceutical Industries in the second quarter worth about $52,000. Finally, Industrial Alliance Investment Management Inc. bought a new stake in Teva Pharmaceutical Industries in the first quarter worth about $54,000. Institutional investors own 54.05% of the company’s stock.

Insider Activity

In other news, insider Eric A. Hughes sold 24,537 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the sale, the insider now owns 45,060 shares of the company’s stock, valued at approximately $777,285. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.55% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on TEVA shares. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Wednesday, July 10th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Finally, UBS Group upped their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $18.89.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded up $0.11 during midday trading on Friday, reaching $17.49. The company had a trading volume of 4,669,458 shares, compared to its average volume of 6,931,503. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. Teva Pharmaceutical Industries Limited has a 1 year low of $8.06 and a 1 year high of $19.08. The company has a market capitalization of $19.81 billion, a P/E ratio of -42.63, a P/E/G ratio of 1.21 and a beta of 0.88. The firm has a 50-day moving average price of $17.83 and a 200-day moving average price of $16.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The business had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. On average, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.